Google's push into artificial intelligence keeps on growing, and 2025 brought a notable entry in the Data Science Agent.

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its shares ...